Cannabis in Cancer Care: From Nausea Control to Potential Tumor-Fighting Properties

What the researchers found

The review covers established and emerging roles of cannabis in cancer care. Established indications include chemotherapy-induced nausea and vomiting (dronabinol is FDA-approved for this) and anorexia associated with AIDS wasting syndrome.

For cancer-related pain, cannabinoids may be beneficial and possibly synergistic with opioid analgesics, potentially allowing lower opioid doses. Research on cannabinoids for HIV-related peripheral neuropathy suggests they may help with cancer-related neuropathic pain as well.

The review also discusses preclinical evidence that cannabinoids may have direct antitumor effects through activation of CB1 and CB2 receptors. However, clinical evidence for antitumor activity is limited. The main limitations of medical cannabinoid use are psychoactive effects and limited bioavailability.

Why it matters

Cancer patients increasingly use cannabis for symptom management, but the evidence base varies greatly by indication. This review provides a structured overview of what is established versus speculative, helping patients and clinicians make informed decisions.

The numbers in context

FDA-approved: dronabinol for chemotherapy nausea and AIDS wasting. Cannabis interacts with CB1 (CNS) and CB2 (immune) receptors. Potential opioid-sparing effects for cancer pain. Preclinical antitumor activity noted.

How the study worked

This is a narrative review covering the pharmacology of cannabinoids in cancer care, including their interaction with the endocannabinoid system, established clinical indications, emerging clinical applications, and preclinical antitumor data.

What this study cannot tell us

Antitumor effects are based on preclinical data only and should not influence treatment decisions. The review does not provide systematic quality assessment of included studies. Cannabinoid bioavailability issues complicate clinical dosing. Psychoactive effects limit dose escalation.

How to read the evidence

This is a narrative review combining well-established clinical evidence (nausea) with emerging clinical (pain) and preclinical (antitumor) data.

When this study was published

Published in 2015. Clinical research on cannabis in oncology has continued to expand.

The bigger picture

Cannabis use in oncology spans a spectrum from well-established (anti-nausea) to speculative (antitumor). This review captures the state of evidence at a time when patient interest in cannabis for cancer was rapidly growing, providing guardrails for clinicians navigating patient requests.

Questions still open

• Will clinical trials confirm antitumor effects of cannabinoids? Can cannabinoid-opioid synergy meaningfully reduce opioid requirements in cancer pain? Would non-psychoactive cannabinoids like CBD offer similar benefits without the psychoactive limitations?

Common questions

Read the original research

Cannabis in cancer care.

Clinical pharmacology and therapeutics, 97(6), 575-86

Citation

Abrams, D I; Guzman, M. (2015). Cannabis in cancer care.. Clinical pharmacology and therapeutics, 97(6), 575-86. https://doi.org/10.1002/cpt.108

Explore the wider topic

• CBD Oil Quality Guide: How to Avoid Snake Oil
• Anxiety After Quitting Weed: When to Consider Medication
• Cannabis for Chemotherapy Nausea: What the Evidence Actually Shows
• Cannabis for Chronic Pain: What the Research Actually Supports
• Cannabis and Epilepsy: The Epidiolex Story and What It Means
• Does CBD Actually Work for Anxiety? What the Evidence Shows
• Does CBD Help with Weed Withdrawal? What Studies Show
• CBD vs THC: The Differences That Actually Matter
• The Proven Medical Benefits of Cannabis: What Research Supports
• Quitting Weed Before Surgery
• Weed and Medications: What Changes When You Quit
• Quitting Weed During Pregnancy: What You Need to Know
• Quitting Weed While Pregnant: What You Need to Know
• Cannabis and Older Adults: Risks Seniors Should Know
• Cannabis and Breastfeeding: THC in Breast Milk